Skip to content
OpenCapital
Get started

Kura Oncology KURA Cash & Equivalents

Cash & Equivalents at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$21.69B-43.6%
Amgen logo
AmgenAMGN
$559M+10.0%
Exelixis logo
ExelixisEXEL
$226.15M+23.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$130.89M-15.0%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$40.1M+702%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M—
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$942.78M+86.2%
Enterprise value$927.97M+95.5%
P/S13.2×+3.9×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's cash & equivalents?
Kura Oncology (KURA) reported cash & equivalents of $39.08M in Q1 2026.
How has Kura Oncology's cash & equivalents changed year-over-year?
Kura Oncology's cash & equivalents decreased by 23.8% year-over-year, from $51.27M to $39.08M.
What is the long-term trend for Kura Oncology's cash & equivalents?
Over 5 years (2020 to 2025), Kura Oncology's cash & equivalents has grown at a -14.5% compound annual growth rate (CAGR), from $325.49M to $149.1M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.